Burden of Respiratory Syncytial Virus (RSV) on Severe Acute Respiratory Infection and Projected Cost Offsets of Implementing a Regional Adult RSV Vaccination Programme
Vaccines · 05.10.2026 · 14 (10) · 882
DOI: 10.3390/vaccines14100882 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 05.10.2026. Verfasst von Liam Townsend und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, St James's Hospital, D08 NHY1 Dublin, Ireland. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
RSV is a significant contributor to severe acute respiratory infection (SARI) admissions. Despite national recommendations for RSV vaccination in Ireland, they have not been implemented due to cost concerns and evidence gaps. We assessed RSV-SARI tertiary healthcare engagement to determine healthcare utilisation costs and potential savings in patients following RSV vaccination.
Methods
RSV SARI admissions over two winter seasons (2024/25 and 2025/26) at a tertiary centre in Ireland were assessed. Sociodemographic and disease-specific variables were recorded, and their relationship with outcomes investigated. Potential cost offsets which may present following a successful RSV vaccination campaign were calculated.
Results
There were 168 RSV admissions during the study (54% aged ≥75). Median length of stay was 6 days and was significantly longer in patients aged ≥75. Having a chronic neurological disease was associated with increased length of stay. The 90-day readmission rate was 24%. Vaccinating ≥75-year-olds in the hospital catchment area would cost €3,712,500, while predicted admission avoidance post-vaccination would save €1,197,692, or €111.77 per vaccine administered. Vaccine costs of €49 would be cost-neutral at the hospital level.
Conclusions
RSV disproportionately affects patients ≥75 years of age. Projected vaccine cost offsets in this population are substantially different from those previously used to inform national policy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Infectious Diseases, St James's Hospital, D08 NHY1 Dublin, Ireland.
- Department of Clinical Medicine, Trinity College Dublin, D02 R590 Dublin, Ireland.
- Department of Respiratory Medicine, St James's Hospital, D08 NHY1 Dublin, Ireland.
- Department of Endocrinology, St James's Hospital, D08 NHY1 Dublin, Ireland.
- Department of Virology, St James's Hospital, D08 NHY1 Dublin, Ireland.
- Department of Medical Gerontology, St James's Hospital, D08 NHY1 Dublin, Ireland.
ORCID-Profile: Liam Townsend, Samuel Zen Kai Yap, Fergal Howley
Zitieren
APA
Townsend, L., Bourke, T. J., Egwu, A., Yap, S. Z. K., Howley, F., Kent, B. D., Woods, C., Conway, A., Crowley, B., Kerr, C., Kenny, R. A., & Bergin, C. (2026). Burden of Respiratory Syncytial Virus (RSV) on Severe Acute Respiratory Infection and Projected Cost Offsets of Implementing a Regional Adult RSV Vaccination Programme. Vaccines, 14(10), 882. https://doi.org/10.3390/vaccines14100882
Vancouver
Townsend L, Bourke TJ, Egwu A, Yap SZK, Howley F, Kent BD, et al. Burden of Respiratory Syncytial Virus (RSV) on Severe Acute Respiratory Infection and Projected Cost Offsets of Implementing a Regional Adult RSV Vaccination Programme. Vaccines. 2026;14(10):882. doi:10.3390/vaccines14100882
BibTeX
@article{Townsend2026,
author = {Townsend, Liam and Bourke, T J and Egwu, Azonim and Yap, Samuel Zen Kai and Howley, Fergal and Kent, Brian D and Woods, Conor and Conway, Aileen and Crowley, Brendan and Kerr, Colm and Kenny, Rose-Anne and Bergin, Colm},
title = {Burden of Respiratory Syncytial Virus (RSV) on Severe Acute Respiratory Infection and Projected Cost Offsets of Implementing a Regional Adult RSV Vaccination Programme},
journal = {Vaccines},
year = {2026},
volume = {14},
number = {10},
pages = {882},
doi = {10.3390/vaccines14100882}
}
EUVIMED